Our technology is unique in the capability to package RNAi-based drugs in crystallized, targeted capsules measuring approximately 10-20 nanometers in diameter. This novel size and structure enables the ‘s50 capsules’ (i.e., capsules measuring less than 50 nanometers in diameter) to bypass the series of biological barriers, including mechanisms of immune activation and drug degradation, that have thus far thwarted commercialization of RNAi-based drugs.

We are dedicated to a partnering business model. Specifically, we are developing partnerships with drug developers to deliver their RNAi molecules into their cell-target of interest by intravenous, subcutaneous, or topical methods. Additionally, we are pursuing partnerships to develop two products discovered in the course of optimizing s50 applications: formulated single-strand RNAi compositions and uses, and s50 companion imaging diagnostics.